Fabrication of an immunosensor for early and ultrasensitive determination of human tissue plasminogen activator (tPA) in myocardial infraction and breast cancer patients

Diagnosis and treatment status of inoperable locally advanced breast cancer and the application value of inorganic nanomaterials

Locally advanced breast cancer (LABC) is a heterogeneous group of breast cancer that accounts for 10-30% of breast cancer cases. Despite the ongoing development of current treatment methods, LABC remains a severe and complex public health concern around the world, thus prompting the urgent requirement for innovative diagnosis and treatment strategies. The primary treatment challenges are inoperable clinical status and ineffective local control methods. With the rapid advancement of nanotechnology, inorganic nanoparticles (INPs) exhibit a potential application prospect in diagnosing and treating breast cancer. Due to the unique inherent characteristics of INPs, different functions can be performed via appropriate modifications and constructions, thus making them suitable for different imaging technology strategies and treatment schemes. INPs can improve the efficacy of conventional local radiotherapy treatment. In the face of inoperable LABC, INPs have proposed new local therapeutic methods and fostered the evolution of novel strategies such as photothermal and photodynamic therapy, magnetothermal therapy, sonodynamic therapy, and multifunctional inorganic nanoplatform. This article reviews the advances of INPs in local accurate imaging and breast cancer treatment and offers insights to overcome the existing clinical difficulties in LABC management.

Electrochemical Nanobiosensors for Detection of Breast Cancer Biomarkers

This comprehensive review paper describes recent advances made in the field of electrochemical nanobiosensors for the detection of breast cancer (BC) biomarkers such as specific genes, microRNA, proteins, circulating tumor cells, BC cell lines, and exosomes or exosome-derived biomarkers. Besides the description of key functional characteristics of electrochemical nanobiosensors, the reader can find basic statistic information about BC incidence and mortality, breast pathology, and current clinically used BC biomarkers. The final part of the review is focused on challenges that need to be addressed in order to apply electrochemical nanobiosensors in a clinical practice.

A portable pencil-like immunosensor for point-of-care testing of inflammatory biomarkers

Portable devices for immunoassays are in high demand for point-of-care testing (POCT) of biomarkers. Here, we report a robust portable pencil-like immunosensor (PPS) platform for the determination of three inflammatory biomarkers including interleukin-6 (IL-6), procalcitonin (PCT), and C-reactive protein (CRP) in human serum samples. The PPS platform is composed of a unique pencil-like optical-fiber-based sensor, a reagent strip consisting of a series of pencil-cap-like wells, and a battery-powered photon counting detector for recording chemiluminescence. The PPS probe moves from well to well with a plug-into/out approach and goes through the immunoassay steps. Each fiber probe in the PPS platform can be sequentially used in up to 10 assays by simply propelling the intact probe out of the pencil body. The PPS platform is well-integrated into a portable suitcase-like device (32 cm × 23 cm × 11 cm) and is only 3 kg in weight. The sensor has good repeatability and can maintain 90% response after 14 days of storage at room temperature, showing its ability for assays in the field. The good linear relationship and efficient dynamic range with a limit-of-detection (LOD) of 1.05 pg/mL for IL-6, 10.64 pg/mL for PCT, and 29.40 ng/mL for CRP are obtained. The assay results are compared with clinical methods, and the findings confirm the high accuracy and precision of the proposed method. The proposed PPS platform is versatile and operable with minimal instruments and technical skills and simplifies the process of immune analysis, thus has great prospects for POCT of biomarkers. Graphical abstract.